Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 9c, Offers Guidance
Get Alerts VNDA Hot Sheet
Price: $4.48 -1.75%
EPS Growth %: -16.7%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
WF, CWBC, GLTO, More
EPS Growth %: -16.7%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $31.85 million versus the consensus estimate of $31.34 million.
2016 Financial Guidance
Vanda expects to achieve the following financial objectives in 2016:
- Net product sales from both HETLIOZ® and Fanapt® of between $143 and $153 million.
- HETLIOZ® net product sales of between $73 and $78 million.
- Fanapt® net product sales of between $70 and $75 million.
- Non-GAAP Operating expenses, excluding cost of goods sold, of between $125 and $135 million. The primary drivers of the expected increase over the prior year are investments in the U.S. Fanapt® and European HETLIOZ® commercial businesses.
- Non-GAAP Operating expenses also excludes intangible asset amortization expense of $10.9 million and stock-based compensation of between $9 and $11 million.
- Year end 2016 Cash is expected to be between $123 million and $143 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!